1: Rochoy M, Auffret M, Béné J, Gautier S; Réseau français des centres régionaux de pharmacovigilance. [Antiemetics and cardiac effects potentially linked to prolongation of the QT interval: Case/non-case analysis in the national pharmacovigilance database]. Rev Epidemiol Sante Publique. 2017 Feb;65(1):1-8. doi: 10.1016/j.respe.2016.06.335. Epub 2016 Dec 14. French. PubMed PMID: 27988172.
2: Mallet E, Bounoure F, Skiba M, Saussereau E, Goullé JP, Castanet M. Pharmacokinetic study of metopimazine by oral route in children. Pharmacol Res Perspect. 2015 Jun;3(3):e00130. doi: 10.1002/prp2.130. Epub 2015 Jun 1. PubMed PMID: 26171218; PubMed Central PMCID: PMC4492748.
3: Roussel V, Tritz T, Souty C, Turbelin C, Arena C, Lambert B, Lillo-Lelouët A, Kernéis S, Blanchon T, Hanslik T. Estimating the excess of inappropriate prescriptions of anti-dopaminergic anti-emetics during acute gastroenteritis epidemics in France. Pharmacoepidemiol Drug Saf. 2013 Oct;22(10):1080-5. doi: 10.1002/pds.3486. Epub 2013 Aug 12. PubMed PMID: 23935001.
4: Hubert-Roux M, Bounoure F, Skiba M, Bozec P, Churlaud F, Lange CM. Fragmentation pathways of metopimazine and its metabolite using ESI-MS(n), HR-MS and H/D exchange. J Mass Spectrom. 2010 Oct;45(10):1121-9. doi: 10.1002/jms.1790. PubMed PMID: 20690157.
5: Naguib IA, Abdelkawy M. Development and validation of stability indicating HPLC and HPTLC methods for determination of sulpiride and mebeverine hydrochloride in combination. Eur J Med Chem. 2010 Sep;45(9):3719-25. doi: 10.1016/j.ejmech.2010.05.021. Epub 2010 May 15. PubMed PMID: 20538381.
6: Kilgore KH, Hill JE, Powell JF, Watson CA, Yanong RP. Investigational use of metomidate hydrochloride as a shipping additive for two ornamental fishes. J Aquat Anim Health. 2009 Sep;21(3):133-9. doi: 10.1577/H08-030.1. PubMed PMID: 20043397.
7: Dupuis LL, Nathan PC. Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines. Paediatr Drugs. 2010;12(1):51-61. doi: 10.2165/11316190-000000000-00000. Review. PubMed PMID: 20034341.
8: Ellebaek E, Herrstedt J. Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. Curr Opin Support Palliat Care. 2008 Mar;2(1):28-34. doi: 10.1097/SPC.0b013e3282f44a75. Review. PubMed PMID: 18685391.
9: Bounoure F, Lahiani Skiba M, Besnard M, Arnaud P, Mallet E, Skiba M. Effect of iontophoresis and penetration enhancers on transdermal absorption of metopimazine. J Dermatol Sci. 2008 Dec;52(3):170-7. doi: 10.1016/j.jdermsci.2008.06.009. Epub 2008 Aug 3. PubMed PMID: 18678472.
10: Frédéric B, Malika LS, Marie H, Eric M, Philippe A, Mohamed S. Percutaneous absorption of metopimazine and effect of cyclodextrins. Drug Dev Ind Pharm. 2008 May;34(5):478-84. doi: 10.1080/03639040701743873 . PubMed PMID: 18473229.
11: Valeyre P, Favier R, Adam M, Quinet B, Grimprel E, Parez N. [Tolerance and efficacy of mefloquine as the first line treatment of uncomplicated P. falciparum malaria in children]. Pathol Biol (Paris). 2008 Feb;56(1):21-8. doi: 10.1016/j.patbio.2007.09.003. Epub 2008 Jan 4. French. PubMed PMID: 18178023.
12: Jolliet P, Nion S, Allain-Veyrac G, Tilloy-Fenart L, Vanuxeem D, Berezowski V, Cecchelli R. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood-brain barrier. Pharmacol Res. 2007 Jul;56(1):11-7. Epub 2006 Dec 19. PubMed PMID: 17572097.
13: Gazy AA, Hassan EM, Abdel-Hay MH, Belal TS. Differential pulse cathodic voltammetric determination of floctafenine and metopimazine. J Pharm Biomed Anal. 2007 Mar 12;43(4):1535-9. Epub 2006 Dec 11. PubMed PMID: 17161576.
14: Herrstedt J, Sigsgaard TC, Nielsen HA, Handberg J, Langer SW, Ottesen S, Dombernowsky P. Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer. 2007 Apr;15(4):417-26. Epub 2006 Nov 9. PubMed PMID: 17093916.
15: Khamales S, Bethune-Volters A, Chidiac J, Bensaoula O, Delgado A, Di Palma M. A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis. Anticancer Drugs. 2006 Feb;17(2):217-24. Erratum in: Anticancer Drugs. 2006 Jun;17(5):599. Khamales, Slimane [added]. PubMed PMID: 16428941.
16: Bloch J, Rixe O, Meric JB, Delgado A, Khayat D. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy. Curr Med Res Opin. 2005 Nov;21(11):1763-71. PubMed PMID: 16307696.
17: Nathan PC, Tomlinson G, Dupuis LL, Greenberg ML, Ota S, Bartels U, Feldman BM. A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design. Support Care Cancer. 2006 Mar;14(3):268-76. Epub 2005 Jul 29. PubMed PMID: 16052316.
18: Dupuis LL, Nathan PC. Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children. Paediatr Drugs. 2003;5(9):597-613. Review. PubMed PMID: 12956617.
19: Sigsgaard T, Herrstedt J, Handberg J, Kjaer M, Dombernowsky P. Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol. 2001 Apr 1;19(7):2091-7. PubMed PMID: 11283143.
20: Sigsgaard T, Herrstedt J, Christensen P, Andersen O, Dombernowsky P. Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy. Support Care Cancer. 2000 May;8(3):233-7. PubMed PMID: 10789966.